Detalhe da pesquisa
1.
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Cancer
; 127(3): 391-402, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119140
2.
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Cancer
; 125(3): 463-472, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383888
3.
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.
Cancer
; 122(21): 3401-3409, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412379
4.
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
Cancer
; 120(15): 2343-51, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24752945
5.
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
Invest New Drugs
; 32(1): 154-9, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23609829
6.
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
Oncologist
; 16(3): 327-35, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21339262
7.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Invest New Drugs
; 29(3): 499-505, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20094773
8.
Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
Clin Lung Cancer
; 22(6): e911-e920, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958300
9.
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
Mol Cancer Ther
; 8(3): 521-32, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19276160
10.
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Oncogene
; 39(49): 7181-7195, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037411
11.
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
Clin Cancer Res
; 13(10): 3006-14, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17505003
12.
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
Clin Lung Cancer
; 19(6): e823-e830, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30369427
13.
Fingerprinting the circulating repertoire of antibodies from cancer patients.
Nat Biotechnol
; 21(1): 57-63, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12496764
14.
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.
J R Stat Soc Ser C Appl Stat
; 66(1): 201-224, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28255183
15.
Lung Cancer in the Older Patient.
Clin Geriatr Med
; 33(4): 563-577, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28991651
16.
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.
Curr Med Res Opin
; 33(5): 937-941, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28277871
17.
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
Clin Lung Cancer
; 7(5): 326-31, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16640804
18.
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
Clin Cancer Res
; 11(10): 3846-53, 2005 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897585
19.
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
Oncotarget
; 7(17): 23227-38, 2016 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933802
20.
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Oncotarget
; 7(41): 67521-67531, 2016 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27589687